Disease on EC 3.4.21.106 - hepsin and Organism(s) Homo sapiens and UniProt Accession P05981
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Adenocarcinoma
Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.
Adenocarcinoma
The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
Adenomatous Polyposis Coli
Concurrent Hepsin overexpression and adenomatous polyposis coli deletion causes invasive prostate carcinoma in mice.
Breast Neoplasms
Bispecific antibodies: a novel approach for targeting prominent biomarkers.
Breast Neoplasms
Cathepsin D enhances breast cancer invasion and metastasis through promoting hepsin ubiquitin-proteasome degradation.
Breast Neoplasms
Clinical and Biological Significance of Hepsin Overexpression in Breast Cancer.
Breast Neoplasms
Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.
Breast Neoplasms
Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology.
Breast Neoplasms
Low expression levels of hepsin and TMPRSS3 are associated with poor breast cancer survival.
Carcinogenesis
A statistical method for identifying differential gene-gene co-expression patterns.
Carcinogenesis
Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.
Carcinogenesis
Design, Synthesis, and Testing of Potent, Selective Hepsin Inhibitors via Application of an Automated Closed-Loop Optimization Platform.
Carcinogenesis
Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers.
Carcinogenesis
Hepatocyte growth factor activator inhibitor-1 (HAI-1) is essential for the integrity of basement membranes in the developing placental labyrinth.
Carcinogenesis
Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.
Carcinogenesis
Oncogenic Ras Disrupts Epithelial Integrity by Activating the Transmembrane Serine Protease Hepsin.
Carcinogenesis
The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
Carcinoma
Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
Carcinoma
Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Carcinoma
Concurrent Hepsin overexpression and adenomatous polyposis coli deletion causes invasive prostate carcinoma in mice.
Carcinoma
Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.
Carcinoma
Expression levels and clinical significance of hepsin and HMGB1 proteins in cervical carcinoma.
Carcinoma
Expression of the factor VII activating protease, hepsin, in situ in renal cell carcinoma.
Carcinoma
Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model.
Carcinoma
Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer.
Carcinoma
Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells.
Carcinoma
Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis.
Carcinoma
The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers?
Carcinoma, Endometrioid
Expression of the serine protease hepsin and clinical outcome of human endometrial cancer.
Carcinoma, Hepatocellular
Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
Carcinoma, Hepatocellular
Autoactivation and calpain-1-mediated shedding of hepsin in human hepatoma cells.
Carcinoma, Hepatocellular
Decreased expressions of hepsin in human hepatocellular carcinomas.
Carcinoma, Hepatocellular
Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer.
Carcinoma, Hepatocellular
Hepsin, a putative cell-surface serine protease, is required for mammalian cell growth.
Carcinoma, Hepatocellular
Mouse matriptase-2: identification, characterization and comparative mRNA expression analysis with mouse hepsin in adult and embryonic tissues.
Carcinoma, Hepatocellular
N-glycan in the scavenger receptor cysteine-rich domain of hepsin promotes intracellular trafficking and cell surface expression.
Carcinoma, Renal Cell
Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
Carcinoma, Renal Cell
Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Carcinoma, Renal Cell
Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.
Carcinoma, Renal Cell
Expression of the factor VII activating protease, hepsin, in situ in renal cell carcinoma.
Carcinoma, Renal Cell
Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model.
Carcinoma, Renal Cell
The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers?
Congenital Abnormalities
Thyroxine treatments do not correct inner ear defects in tmprss1 mutant mice.
Endometrial Hyperplasia
Expression of the serine protease hepsin and clinical outcome of human endometrial cancer.
Endometrial Neoplasms
Expression of the serine protease hepsin and clinical outcome of human endometrial cancer.
Endometriosis
CD44, TGM2 and EpCAM as novel plasma markers in endometrial cancer diagnosis.
Hearing Loss
An integrated genetic and functional analysis of the role of type II transmembrane serine proteases (TMPRSSs) in hearing loss.
Hepatitis B
Hepatitis B virus X protein binding to hepsin promotes C3 production by inducing IL-6 secretion from hepatocytes.
Hepatitis B
Human hepatitis B virus X protein promotes cell proliferation and inhibits cell apoptosis through interacting with a serine protease Hepsin.
hepsin deficiency
Generation and characterization of mice deficient in hepsin, a hepatic transmembrane serine protease.
hepsin deficiency
Hepsin enhances liver metabolism and inhibits adipocyte browning in mice.
hepsin deficiency
Hepsin Promotes Epithelial-Mesenchymal Transition and Cell Invasion Through the miR-222/PPP2R2A/AKT Axis in Prostate Cancer.
Herpes Zoster
The serine protease hepsin mediates urinary secretion and polymerisation of Zona Pellucida domain protein uromodulin.
Immune System Diseases
Proteolytic activation of pro-macrophage-stimulating protein by hepsin.
Kidney Calculi
Design of drug-like hepsin inhibitors against prostate cancer and kidney stones.
Lymphatic Metastasis
Expression levels and clinical significance of hepsin and HMGB1 proteins in cervical carcinoma.
Lymphatic Metastasis
Expression of the serine protease hepsin and clinical outcome of human endometrial cancer.
Neoplasm Metastasis
?-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer.
Neoplasm Metastasis
Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
Neoplasm Metastasis
Autoactivation and calpain-1-mediated shedding of hepsin in human hepatoma cells.
Neoplasm Metastasis
Cathepsin D enhances breast cancer invasion and metastasis through promoting hepsin ubiquitin-proteasome degradation.
Neoplasm Metastasis
Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Neoplasm Metastasis
Design, Synthesis, and Testing of Potent, Selective Hepsin Inhibitors via Application of an Automated Closed-Loop Optimization Platform.
Neoplasm Metastasis
Expression levels and clinical significance of hepsin and HMGB1 proteins in cervical carcinoma.
Neoplasm Metastasis
Expression of the serine protease hepsin and clinical outcome of human endometrial cancer.
Neoplasm Metastasis
Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
Neoplasm Metastasis
Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.
Neoplasm Metastasis
Identification and characterization of small-molecule inhibitors of hepsin.
Neoplasm Metastasis
Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.
Neoplasm Metastasis
Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis.
Neoplasm Metastasis
Serine protease hepsin regulates hepatocyte size and hemodynamic retention of tumor cells via hepatocyte growth factor signaling.
Neoplasm Metastasis
Structure-activity relationship studies of dipeptide-based hepsin inhibitors with Arg bioisosteres.
Neoplasm Metastasis
Structure-based design, synthesis, and biological evaluation of Leu-Arg dipeptide analogs as novel hepsin inhibitors.
Neoplasm Metastasis
Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors.
Neoplasm Metastasis
Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis.
Neoplasm Metastasis
The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
Neoplasms
?-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer.
Neoplasms
A novel knock-in prostate cancer model demonstrates biology similar to that of human prostate cancer and suitable for preclinical studies.
Neoplasms
A statistical method for identifying differential gene-gene co-expression patterns.
Neoplasms
An allosteric anti-hepsin antibody derived from a constrained phage display library.
Neoplasms
Analyzing the Type II Transmembrane Serine Protease Hepsin-Dependent Basement Membrane Remodeling in 3D Cell Culture.
Neoplasms
Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
Neoplasms
Autoactivation and calpain-1-mediated shedding of hepsin in human hepatoma cells.
Neoplasms
Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Neoplasms
Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.
Neoplasms
Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands.
Neoplasms
Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases.
Neoplasms
Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology.
Neoplasms
Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.
Neoplasms
Excess hepsin proteolytic activity limits oncogenic signaling and induces ER stress and autophagy in prostate cancer cells.
Neoplasms
Expression levels and clinical significance of hepsin and HMGB1 proteins in cervical carcinoma.
Neoplasms
Expression of the serine protease hepsin and clinical outcome of human endometrial cancer.
Neoplasms
Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.
Neoplasms
Gene expression profiles in prostate cancer: association with patient subgroups and tumour differentiation.
Neoplasms
Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.
Neoplasms
Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
Neoplasms
Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer.
Neoplasms
Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model.
Neoplasms
Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.
Neoplasms
Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer.
Neoplasms
Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer.
Neoplasms
Human hepatitis B virus X protein promotes cell proliferation and inhibits cell apoptosis through interacting with a serine protease Hepsin.
Neoplasms
Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.
Neoplasms
Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.
Neoplasms
Low expression levels of hepsin and TMPRSS3 are associated with poor breast cancer survival.
Neoplasms
Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells.
Neoplasms
N-glycan in the scavenger receptor cysteine-rich domain of hepsin promotes intracellular trafficking and cell surface expression.
Neoplasms
Oncogenic Ras Disrupts Epithelial Integrity by Activating the Transmembrane Serine Protease Hepsin.
Neoplasms
Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis.
Neoplasms
Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
Neoplasms
Pericellular regulation of prostate cancer expressed kallikrein-related peptidases and matrix metalloproteinases by cell surface serine proteases.
Neoplasms
pH-sensitive PEGylation of RIPL peptide-conjugated nanostructured lipid carriers: design and in vitro evaluation.
Neoplasms
RIPL peptide (IPLVVPLRRRRRRRRC)-conjugated liposomes for enhanced intracellular drug delivery to hepsin-expressing cancer cells.
Neoplasms
RIPL peptide-conjugated nanostructured lipid carriers for enhanced intracellular drug delivery to hepsin-expressing cancer cells.
Neoplasms
Serine protease hepsin regulates hepatocyte size and hemodynamic retention of tumor cells via hepatocyte growth factor signaling.
Neoplasms
Structure-activity relationship studies of dipeptide-based hepsin inhibitors with Arg bioisosteres.
Neoplasms
Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors.
Neoplasms
Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis.
Neoplasms
The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
Neoplasms
The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers?
Neoplasms
The serine proteinase hepsin is an activator of pro-matrix metalloproteinases: molecular mechanisms and implications for extracellular matrix turnover.
Neoplasms
The structure of the extracellular region of human hepsin reveals a serine protease domain and a novel scavenger receptor cysteine-rich (SRCR) domain.
Ovarian Neoplasms
Analyzing the Type II Transmembrane Serine Protease Hepsin-Dependent Basement Membrane Remodeling in 3D Cell Culture.
Ovarian Neoplasms
Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer.
Ovarian Neoplasms
Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.
Ovarian Neoplasms
Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model.
Ovarian Neoplasms
Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines.
Ovarian Neoplasms
Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer.
Ovarian Neoplasms
Identification of Hepsin and Protein Disulfide Isomerase A3 as Targets of Gelatinolytic Action in Rat Ovarian Granulosa Cells During the Periovulatory Period.
Prostatic Hyperplasia
Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer.
Prostatic Neoplasms
Alpha-methylacyl-CoA racemase and hepsin as urinary prostate cancer markers.
Prostatic Neoplasms
An allosteric anti-hepsin antibody derived from a constrained phage display library.
Prostatic Neoplasms
Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
Prostatic Neoplasms
Association of hepsin gene variants with prostate cancer risk and prognosis.
Prostatic Neoplasms
Bispecific antibodies: a novel approach for targeting prominent biomarkers.
Prostatic Neoplasms
Characterization of a method for profiling gene expression in cells recovered from intact human prostate tissue using RNA linear amplification.
Prostatic Neoplasms
Concurrent Hepsin overexpression and adenomatous polyposis coli deletion causes invasive prostate carcinoma in mice.
Prostatic Neoplasms
Correction: Excess hepsin proteolytic activity limits oncogenic signaling and induces ER stress and autophagy in prostate cancer cells.
Prostatic Neoplasms
Design of drug-like hepsin inhibitors against prostate cancer and kidney stones.
Prostatic Neoplasms
Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands.
Prostatic Neoplasms
Detection of early prostate cancer using a hepsin-targeted imaging agent.
Prostatic Neoplasms
Development of an Activatable Fluorescent Probe for Prostate Cancer Imaging.
Prostatic Neoplasms
Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer.
Prostatic Neoplasms
Emerging biomarkers for the diagnosis and prognosis of prostate cancer.
Prostatic Neoplasms
Excess hepsin proteolytic activity limits oncogenic signaling and induces ER stress and autophagy in prostate cancer cells.
Prostatic Neoplasms
From in-silico to Experimental Validation: Tailoring Peptide Substrates for a Serine Protease.
Prostatic Neoplasms
Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
Prostatic Neoplasms
Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer.
Prostatic Neoplasms
Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model.
Prostatic Neoplasms
Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.
Prostatic Neoplasms
Hepsin immunohistochemical expression in prostate cancer in relation to Gleason's grade and serum prostate specific antigen.
Prostatic Neoplasms
Hepsin inhibits CDK11p58 IRES activity by suppressing unr expression and eIF-2? phosphorylation in prostate cancer.
Prostatic Neoplasms
Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer.
Prostatic Neoplasms
Hepsin Promotes Epithelial-Mesenchymal Transition and Cell Invasion Through the miR-222/PPP2R2A/AKT Axis in Prostate Cancer.
Prostatic Neoplasms
HLA-A2-restricted Cytotoxic T Lymphocyte Epitopes from Human Hepsin as Novel Targets for Prostate Cancer Immunotherapy.
Prostatic Neoplasms
Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling.
Prostatic Neoplasms
Identification and characterization of small-molecule inhibitors of hepsin.
Prostatic Neoplasms
Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing.
Prostatic Neoplasms
Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues.
Prostatic Neoplasms
Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.
Prostatic Neoplasms
Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells.
Prostatic Neoplasms
Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease.
Prostatic Neoplasms
Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer.
Prostatic Neoplasms
Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis.
Prostatic Neoplasms
Proteolytic activation of pro-macrophage-stimulating protein by hepsin.
Prostatic Neoplasms
Structure-activity relationship studies of dipeptide-based hepsin inhibitors with Arg bioisosteres.
Prostatic Neoplasms
Structure-based design, synthesis, and biological evaluation of Leu-Arg dipeptide analogs as novel hepsin inhibitors.
Prostatic Neoplasms
Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors.
Prostatic Neoplasms
Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis.
Prostatic Neoplasms
TMEFF2 shedding is regulated by oxidative stress and mediated by ADAMs and transmembrane serine proteases implicated in prostate cancer.
Prostatic Neoplasms
Use of multiple biomarkers for a molecular diagnosis of prostate cancer.
Prostatic Neoplasms
Variants in the HEPSIN gene are associated with prostate cancer in men of European origin.
Prostatic Neoplasms
Variants in the HEPSIN gene are associated with susceptibility to prostate cancer.
Sarcoma
Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis.
Synovitis
The serine proteinase hepsin is an activator of pro-matrix metalloproteinases: molecular mechanisms and implications for extracellular matrix turnover.
Urologic Neoplasms
Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.
Virus Diseases
The transmembrane serine protease hepsin suppresses type I interferon induction by cleaving STING.